![[Toyota Times] From Strengthening Foundations to Boosting Productivity - Toyota Focuses on Break-Even Volume](https://businessfortnight.com/wp-content/uploads/2025/11/Toyota-Times-From-Strengthening-Foundations-to-Boosting-Productivity-Toyota-218x150.jpg "[Toyota Times] From Strengthening Foundations to Boosting Productivity – Toyota Focuses on Break-Even Volume")
SEONGDONG-GU, SEOUL, SOUTH KOREA, October 24, 2022 /EINPresswire.com/ — MDimune, Inc., a Korean biotech firm growing BioDroneTM platform expertise based mostly on cell-derived vesicles (CDVs), enters into an MOU with SensoryCure to collaborate on the event of therapeutics for hearing loss. SensoryCure is a firm established by otolaryngology specialists, Dr. Bong Jik Kim (Chungnam National University Sejong Hospital, Korea) and Dr. Byung-Yoon Choi (Seoul National University Bundang Hospital, Korea) to develop diagnostic units and present modern cures for sufferers affected by hearing loss.
In latest publications, Dr. Kim and Dr. Choi reported the affect of genetic contribution to pediatric mild-to-moderate hearing loss and profitable long-term audiologic outcomes of cochlear implantation in sufferers with cochlear aplasia, which is taken into account one of the crucial extreme types of cochlear impairment. They additionally recognized a number of genetic variants which contribute to malformation and hearing loss and established the medical guideline to deal with autoinflammatory inside ear dysfunction.
MDimune develops BioDrone™ platform expertise which makes use of CDVs obtained from its proprietary extrusion expertise as a next-generation drug supply system. This novel class of drug carriers is very versatile and might be generated from numerous sorts of human cells at excessive manufacturing yields. The collaboration goals to reveal the efficacy of CDVs as a therapeutic for autoinflammatory hearing loss and commercialize the product.
Shingyu Bae, the CEO of MDimune addressed, “we have been working on the development of therapeutics for debilitating diseases. We are very excited to work with SensoryCure, the leading expert in the hearing loss field. We will also expand our research to build a gene therapy platform in hearing loss.”
Dr. Bong Jik Kim, the CEO of SensoryCure, added, “we are very pleased to collaborate with MDimune to develop therapeutics for hearing loss using their world-class technology.”
Jisun Lee
MDimune Inc.
e-mail us right here
Visit us on social media:
Facebook
